Precision Medicine


Precision medicine is an approach that tailor’s medical treatment to the specific characteristics of an individual’s disease, considering factors such as genetics, environment, and lifestyle. This personalized approach has the potential to significantly improve outcomes for individuals with various conditions, including ALS.  

In ALS, precision medicine may involve collecting extensive information from participants, such as genetic data, biomarkers, and clinical information. Analyzing this data can help researchers identify specific molecular drivers of the disease, allowing for more targeted and effective interventions. The goal is to better understand the underlying mechanisms of ALS at an individual level and develop more personalized and efficient treatments. 

By leveraging emerging biomedical technologies and incorporating a large amount of data, precision medicine holds the promise of making novel discoveries and advancements in the understanding and treatment of ALS. It reflects a shift towards more individualized and tailored healthcare, with the aim of improving the quality of life for people living with ALS. 

Learn More

Center for Genomics of Neurodegenerative Disease (CGND): The CGND, particularly the Phatnani Lab at the New York Genome Center, focuses on studying neurodegenerative diseases, including ALS, by applying genetics, genomics, and bioinformatics to understand the underlying mechanisms.

CReATe Therapies for ALS & Related Disorders: This initiative, part of the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) program, aims to develop therapies for ALS through clinical research. 

Answer ALS Research Program: The Answer ALS Research Program uses multi-omics analysis to assess motor neuron function in people with ALS compared to healthy individuals. 

NeuroLINCS Center: The NeuroLINCS Center is an NIH-funded collaborative initiative involving multiple research groups with expertise in iPSC technology, disease modeling, OMICS methods (such as genomics, transcriptomics, and proteomics), and computational biology.

Project MinE: The primary goal of Project MinE is to analyze the DNA of a substantial number of ALS patients and controls to identify genetic factors associated with the disease. 

National Institutes of Health: The Promise of Precision Medicine: The NIH explores the promise of precision medicine, emphasizing its potential impact on healthcare and treatment strategies.

From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis" (Frontiers in Neuroscience, 2020):